ArticleThe journal of allergy and clinical immunology. Global2025
Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dupilumab was approved as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps based on the pivotal phase 3 trials. Objective: Our aim was to assess patients' adherence to and persistence with dupilumab treatment in a real-world setting. Methods: Patients aged 18 to 64 years who initiated dupilumab treatment between June 26, 2019, and December 31, 2021, were identified by using the IQVIA PharMetrics Plus claims database. Patients were required to have at least 12 months of continuous enrollment (baseline period) before the first recorded dispensing of dupilumab and at least 1 diagnosis of chronic rhinosinusitis with nasal polyps during the baseline period. Follow-up was censored at health plan disenrollment or on December 31, 2021. Baseline demographic and clinical characteristics as well as persistence with dupilumab treatment, adherence to dupilumab treatment regimen, discontinuation of dupilumab treatment, and reinitiation of dupilumab treatment were assessed during the follow-up period. A time-to-event analysis was conducted to assess the probability of persistence with and reinitiation of dupilumab treatment at 6 and 12 months. Results: The 3318 patients included had a mean age of 47.1 years (SD = 11.1 years); 54.4% were male. After initiation of dupilumab treatment, the probabilities of persisting with dupilumab treatment were 84.9% and 69.5% at 6 and 12 months, respectively, with 75.2% of patients adhering to dupilumab treatment during the persistence period. Approximately 43.3% of patients who discontinued dupilumab treatment resumed it within 12 months, with the median time to reinitiation being 1.2 months. Conclusion: Persistence with dupilumab treatment remained high at 12 months, with more than 40.0% of patients who discontinued dupilumab treatment reinitiating it within 12 months in this real-world practice setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.